


## BDP9066

<b>Cat. No.:</b>	HY-111424		
<b>CAS No.:</b>	2226507-04-4		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>24</sub> N <sub>6</sub>		
<b>Molecular Weight:</b>	348.44		
<b>Target:</b>	Ras		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 10 mg/mL (28.70 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	<b>Preparing Stock Solutions</b>		10 mg	
	<b>1 mM</b>	2.8699 mL	14.3497 mL	28.6993 mL
	<b>5 mM</b>	0.5740 mL	2.8699 mL	5.7399 mL
	<b>10 mM</b>	0.2870 mL	1.4350 mL	2.8699 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (2.87 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (2.87 mM); Clear solution			

## BIOLOGICAL ACTIVITY

<b>Description</b>	BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC <sub>50</sub> of 64 nM for MRCKβ in SCC12 cells, K <sub>i</sub> values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 64 nM (MRCKβ in SCC12 cells), K <sub>i</sub> : 0.0136 nM/0.0233 nM (MRCKα/β) <sup>[1]</sup> .
<b>In Vitro</b>	BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**In Vivo**

BDP9066 topical application significantly decreases phosphorylated MRCK $\alpha$  S1003 staining and tumor volumes<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**REFERENCES**

[1]. Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA